Nitric oxide-donating aspirin (NO-ASA) is a promising agent for cancer prevention. Although
studied extensively, its molecular targets and mechanism of action are still unclear. S …

Nitric oxide (NO)-releasing aspirin (ASA), consisting of a traditional ASA molecule to which a
NO-donating moiety is covalently bound, is a promising colon cancer chemopreventive …

Nitric oxide-donating aspirin (NO-ASA) is a promising agent for the control of cancer, whose
mechanism of action remains unclear. NF-κB is an important signaling molecule in the …

NO-NSAIDs are promising anticancer drugs, comprising an NSAID, an NO-releasing moiety,
and a spacer linking them. Although the effect of NO-NSAIDs on a wide variety of signaling …

Nitric oxide-releasing aspirin (NO-ASA) is emerging as a potentially important
chemopreventive agent against colon cancer. We examined in HT-29 human colon …

Nitric-oxide-donating aspirin (NO-ASA), consisting of ASA (aspirin) plus an-ONO2 moiety
linked to it via a molecular spacer, is a new drug for cancer prevention. NO-ASA seems to …

Nitric oxide-donating aspirin (NO-aspirin), representing a new concept in the development of
more efficacious nonsteroidal anti-inflammatory drugs, consists of traditional aspirin bearing …

Nitric-oxide-donating nonsteroidal anti-inflammatory drugs (NO–NSAIDs), which consist of
an NSAID with an NO-donating moiety covalently attached to it, promise to contribute …

Nitric oxide-donating aspirin (NO-ASA) is a promising chemoprevention agent against colon
cancer and other cancers. It consists of traditional ASA to which a NO-releasing moiety is …

NO (nitric oxide) biology has provided the impetus for the development of anticancer agents
based on their ability to release NO. NO-NSAIDs (NO-donating non-steroidal anti …